Impaired endothelium-dependent vasodilation in overweight and obese adult humans is not limited to muscarinic receptor agonists

1 Integrative Vascular Biology Laboratory, Department of Integrative Physiology, University of Colorado, Boulder; 2 Department of Medicine, University of Colorado Health Sciences Center, and 3 Division of Cardiology, Department of Medicine, Denver Health and Hospital Authority, Denver, Colorado Subm...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:American journal of physiology. Heart and circulatory physiology 2008-04, Vol.294 (4), p.H1685-H1692
Hauptverfasser: Van Guilder, Gary P, Stauffer, Brian L, Greiner, Jared J, DeSouza, Christopher A
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page H1692
container_issue 4
container_start_page H1685
container_title American journal of physiology. Heart and circulatory physiology
container_volume 294
creator Van Guilder, Gary P
Stauffer, Brian L
Greiner, Jared J
DeSouza, Christopher A
description 1 Integrative Vascular Biology Laboratory, Department of Integrative Physiology, University of Colorado, Boulder; 2 Department of Medicine, University of Colorado Health Sciences Center, and 3 Division of Cardiology, Department of Medicine, Denver Health and Hospital Authority, Denver, Colorado Submitted 1 November 2007 ; accepted in final form 13 February 2008 Muscarinic receptor agonists have primarily been used to characterize endothelium-dependent vasodilator dysfunction with overweight/obesity. Reliance on a single class of agonist, however, yields limited, and potentially misleading, information regarding endothelial vasodilator capacity. The aims of this study were to determine 1 ) whether the overweight/obesity-related reduction in endothelium-dependent vasodilation extends beyond muscarinic receptor agonists and 2 ) whether the contribution of nitric oxide (NO) to endothelium-dependent vasodilation is reduced in overweight/obese adults. Eighty-six middle-aged and older adults were studied: 42 normal-weight (54 ± 1 yr, 21 men and 21 women, body mass index = 23.4 ± 0.3 kg/m 2 ) and 44 overweight/obese (54 ± 1 yr, 28 men and 16 women, body mass index = 30.3 ± 0.6 kg/m 2 ) subjects. Forearm blood flow (FBF) responses to intra-arterial infusions of acetylcholine in the absence and presence of the endothelial NO synthase inhibitor N G -monomethyl- L -arginine, methacholine, bradykinin, substance P, isoproterenol, and sodium nitroprusside were measured by strain-gauge plethysmography. FBF responses to each endothelial agonist were significantly blunted in the overweight/obese adults. Total FBF (area under the curve) to acetylcholine (50 ± 5 vs. 79 ± 4 ml/100 ml tissue), methacholine (55 ± 4 vs. 86 ± 5 ml/100 ml tissue), bradykinin (62 ± 5 vs. 85 ± 4 ml/100 ml tissue), substance P (37 ± 4 vs. 57 ± 5 ml/100 ml tissue), and isoproterenol (62 ± 4 vs. 82 ± 6 ml/100 ml tissue) were 30%-40% lower in the overweight/obese than normal-weight adults. N G -monomethyl- L -arginine significantly reduced the FBF response to acetylcholine to the same extent in both groups. There were no differences between the groups in the FBF responses to sodium nitroprusside. These results indicate that agonist-stimulated endothelium-dependent vasodilation is universally impaired with overweight/obesity. Moreover, this impairment appears to be independent of NO. cell surface receptors; intracellular signaling pathways; nitric oxide Address for reprint requests and other correspondenc
doi_str_mv 10.1152/ajpheart.01281.2007
format Article
fullrecord <record><control><sourceid>proquest_highw</sourceid><recordid>TN_cdi_highwire_physiology_ajpheart_294_4_H1685</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1460409201</sourcerecordid><originalsourceid>FETCH-LOGICAL-c522t-edf2d1e5e6ef9af8c8a6272525fcfd08e5e4b503ffe4c48a0d60fee861b5f6d13</originalsourceid><addsrcrecordid>eNp1UV2LEzEUDaK4dfUXCBJ8n24-JukMgiCL6y4s-LI-h3Ry00mZScYk07VP_nVTW-v64FMI5-Oeew9CbylZUirYld5OPeiYl4Syhi4ZIatnaFEQVlHB2-doQbjklaRcXKBXKW0JIWIl-Ut0QZui4Kt2gX7ejZN2EQwGb0LuYXDzWBmYyhd8xjudgnGDzi547DwOO4iP4DZ9xtobHNaQAGszDxn386h9wi5hHzIe3Ohysc0Bj3PqdHTedThCB1MOEetN8C7l9Bq9sHpI8Ob0XqJvN58frm-r-69f7q4_3Vdd2SdXYCwzFARIsK22TddoyVZMMGE7a0hTkHotCLcW6q5uNDGSWIBG0rWw0lB-iT4efad5PYLpym5RD2qKbtRxr4J26l_Eu15twk5xWUxoXQzenwxi-D5Dymob5uhLZsVYK0UryGEKP5K6GFKKYM8DKFGH0tSf0tTv0tShtKJ69zTbX82ppUL4cCT05fCPpS019fvkwhA2e3UzD8MD_Mhna9bWqla3VDZCTcYW9dX_1ec8T1T8F4n6wV4</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>229659501</pqid></control><display><type>article</type><title>Impaired endothelium-dependent vasodilation in overweight and obese adult humans is not limited to muscarinic receptor agonists</title><source>MEDLINE</source><source>American Physiological Society</source><source>Alma/SFX Local Collection</source><source>EZB Electronic Journals Library</source><creator>Van Guilder, Gary P ; Stauffer, Brian L ; Greiner, Jared J ; DeSouza, Christopher A</creator><creatorcontrib>Van Guilder, Gary P ; Stauffer, Brian L ; Greiner, Jared J ; DeSouza, Christopher A</creatorcontrib><description>1 Integrative Vascular Biology Laboratory, Department of Integrative Physiology, University of Colorado, Boulder; 2 Department of Medicine, University of Colorado Health Sciences Center, and 3 Division of Cardiology, Department of Medicine, Denver Health and Hospital Authority, Denver, Colorado Submitted 1 November 2007 ; accepted in final form 13 February 2008 Muscarinic receptor agonists have primarily been used to characterize endothelium-dependent vasodilator dysfunction with overweight/obesity. Reliance on a single class of agonist, however, yields limited, and potentially misleading, information regarding endothelial vasodilator capacity. The aims of this study were to determine 1 ) whether the overweight/obesity-related reduction in endothelium-dependent vasodilation extends beyond muscarinic receptor agonists and 2 ) whether the contribution of nitric oxide (NO) to endothelium-dependent vasodilation is reduced in overweight/obese adults. Eighty-six middle-aged and older adults were studied: 42 normal-weight (54 ± 1 yr, 21 men and 21 women, body mass index = 23.4 ± 0.3 kg/m 2 ) and 44 overweight/obese (54 ± 1 yr, 28 men and 16 women, body mass index = 30.3 ± 0.6 kg/m 2 ) subjects. Forearm blood flow (FBF) responses to intra-arterial infusions of acetylcholine in the absence and presence of the endothelial NO synthase inhibitor N G -monomethyl- L -arginine, methacholine, bradykinin, substance P, isoproterenol, and sodium nitroprusside were measured by strain-gauge plethysmography. FBF responses to each endothelial agonist were significantly blunted in the overweight/obese adults. Total FBF (area under the curve) to acetylcholine (50 ± 5 vs. 79 ± 4 ml/100 ml tissue), methacholine (55 ± 4 vs. 86 ± 5 ml/100 ml tissue), bradykinin (62 ± 5 vs. 85 ± 4 ml/100 ml tissue), substance P (37 ± 4 vs. 57 ± 5 ml/100 ml tissue), and isoproterenol (62 ± 4 vs. 82 ± 6 ml/100 ml tissue) were 30%-40% lower in the overweight/obese than normal-weight adults. N G -monomethyl- L -arginine significantly reduced the FBF response to acetylcholine to the same extent in both groups. There were no differences between the groups in the FBF responses to sodium nitroprusside. These results indicate that agonist-stimulated endothelium-dependent vasodilation is universally impaired with overweight/obesity. Moreover, this impairment appears to be independent of NO. cell surface receptors; intracellular signaling pathways; nitric oxide Address for reprint requests and other correspondence: C. A. DeSouza, Dept. of Integrative Physiology, Univ. of Colorado, 354 UCB, Boulder, CO 80309 (e-mail: desouzac{at}colorado.edu )</description><identifier>ISSN: 0363-6135</identifier><identifier>EISSN: 1522-1539</identifier><identifier>DOI: 10.1152/ajpheart.01281.2007</identifier><identifier>PMID: 18281379</identifier><identifier>CODEN: AJPPDI</identifier><language>eng</language><publisher>United States: American Physiological Society</publisher><subject><![CDATA[Acetylcholine - administration & dosage ; Adult ; Aged ; Blood vessels ; Body Mass Index ; Bradykinin - administration & dosage ; Cells ; Dose-Response Relationship, Drug ; Endothelium, Vascular - drug effects ; Endothelium, Vascular - enzymology ; Endothelium, Vascular - metabolism ; Endothelium, Vascular - physiopathology ; Enzyme Inhibitors - administration & dosage ; Female ; Forearm - blood supply ; Humans ; Infusions, Intravenous ; Isoproterenol - administration & dosage ; Male ; Methacholine Chloride - administration & dosage ; Middle Aged ; Muscarinic Agonists - administration & dosage ; NG-Nitroarginine Methyl Ester - administration & dosage ; Nitric oxide ; Nitric Oxide - metabolism ; Nitric Oxide Synthase - antagonists & inhibitors ; Nitric Oxide Synthase - metabolism ; Nitroprusside - administration & dosage ; Obesity ; Obesity - metabolism ; Obesity - physiopathology ; Regional Blood Flow - drug effects ; Signal Transduction - drug effects ; Studies ; Substance P - administration & dosage ; Vasodilation - drug effects ; Vasodilator Agents - administration & dosage]]></subject><ispartof>American journal of physiology. Heart and circulatory physiology, 2008-04, Vol.294 (4), p.H1685-H1692</ispartof><rights>Copyright American Physiological Society Apr 2008</rights><rights>Copyright © 2008 the American Physiological Society 2008</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c522t-edf2d1e5e6ef9af8c8a6272525fcfd08e5e4b503ffe4c48a0d60fee861b5f6d13</citedby><cites>FETCH-LOGICAL-c522t-edf2d1e5e6ef9af8c8a6272525fcfd08e5e4b503ffe4c48a0d60fee861b5f6d13</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,315,781,785,886,3040,27926,27927</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18281379$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Van Guilder, Gary P</creatorcontrib><creatorcontrib>Stauffer, Brian L</creatorcontrib><creatorcontrib>Greiner, Jared J</creatorcontrib><creatorcontrib>DeSouza, Christopher A</creatorcontrib><title>Impaired endothelium-dependent vasodilation in overweight and obese adult humans is not limited to muscarinic receptor agonists</title><title>American journal of physiology. Heart and circulatory physiology</title><addtitle>Am J Physiol Heart Circ Physiol</addtitle><description>1 Integrative Vascular Biology Laboratory, Department of Integrative Physiology, University of Colorado, Boulder; 2 Department of Medicine, University of Colorado Health Sciences Center, and 3 Division of Cardiology, Department of Medicine, Denver Health and Hospital Authority, Denver, Colorado Submitted 1 November 2007 ; accepted in final form 13 February 2008 Muscarinic receptor agonists have primarily been used to characterize endothelium-dependent vasodilator dysfunction with overweight/obesity. Reliance on a single class of agonist, however, yields limited, and potentially misleading, information regarding endothelial vasodilator capacity. The aims of this study were to determine 1 ) whether the overweight/obesity-related reduction in endothelium-dependent vasodilation extends beyond muscarinic receptor agonists and 2 ) whether the contribution of nitric oxide (NO) to endothelium-dependent vasodilation is reduced in overweight/obese adults. Eighty-six middle-aged and older adults were studied: 42 normal-weight (54 ± 1 yr, 21 men and 21 women, body mass index = 23.4 ± 0.3 kg/m 2 ) and 44 overweight/obese (54 ± 1 yr, 28 men and 16 women, body mass index = 30.3 ± 0.6 kg/m 2 ) subjects. Forearm blood flow (FBF) responses to intra-arterial infusions of acetylcholine in the absence and presence of the endothelial NO synthase inhibitor N G -monomethyl- L -arginine, methacholine, bradykinin, substance P, isoproterenol, and sodium nitroprusside were measured by strain-gauge plethysmography. FBF responses to each endothelial agonist were significantly blunted in the overweight/obese adults. Total FBF (area under the curve) to acetylcholine (50 ± 5 vs. 79 ± 4 ml/100 ml tissue), methacholine (55 ± 4 vs. 86 ± 5 ml/100 ml tissue), bradykinin (62 ± 5 vs. 85 ± 4 ml/100 ml tissue), substance P (37 ± 4 vs. 57 ± 5 ml/100 ml tissue), and isoproterenol (62 ± 4 vs. 82 ± 6 ml/100 ml tissue) were 30%-40% lower in the overweight/obese than normal-weight adults. N G -monomethyl- L -arginine significantly reduced the FBF response to acetylcholine to the same extent in both groups. There were no differences between the groups in the FBF responses to sodium nitroprusside. These results indicate that agonist-stimulated endothelium-dependent vasodilation is universally impaired with overweight/obesity. Moreover, this impairment appears to be independent of NO. cell surface receptors; intracellular signaling pathways; nitric oxide Address for reprint requests and other correspondence: C. A. DeSouza, Dept. of Integrative Physiology, Univ. of Colorado, 354 UCB, Boulder, CO 80309 (e-mail: desouzac{at}colorado.edu )</description><subject>Acetylcholine - administration &amp; dosage</subject><subject>Adult</subject><subject>Aged</subject><subject>Blood vessels</subject><subject>Body Mass Index</subject><subject>Bradykinin - administration &amp; dosage</subject><subject>Cells</subject><subject>Dose-Response Relationship, Drug</subject><subject>Endothelium, Vascular - drug effects</subject><subject>Endothelium, Vascular - enzymology</subject><subject>Endothelium, Vascular - metabolism</subject><subject>Endothelium, Vascular - physiopathology</subject><subject>Enzyme Inhibitors - administration &amp; dosage</subject><subject>Female</subject><subject>Forearm - blood supply</subject><subject>Humans</subject><subject>Infusions, Intravenous</subject><subject>Isoproterenol - administration &amp; dosage</subject><subject>Male</subject><subject>Methacholine Chloride - administration &amp; dosage</subject><subject>Middle Aged</subject><subject>Muscarinic Agonists - administration &amp; dosage</subject><subject>NG-Nitroarginine Methyl Ester - administration &amp; dosage</subject><subject>Nitric oxide</subject><subject>Nitric Oxide - metabolism</subject><subject>Nitric Oxide Synthase - antagonists &amp; inhibitors</subject><subject>Nitric Oxide Synthase - metabolism</subject><subject>Nitroprusside - administration &amp; dosage</subject><subject>Obesity</subject><subject>Obesity - metabolism</subject><subject>Obesity - physiopathology</subject><subject>Regional Blood Flow - drug effects</subject><subject>Signal Transduction - drug effects</subject><subject>Studies</subject><subject>Substance P - administration &amp; dosage</subject><subject>Vasodilation - drug effects</subject><subject>Vasodilator Agents - administration &amp; dosage</subject><issn>0363-6135</issn><issn>1522-1539</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1UV2LEzEUDaK4dfUXCBJ8n24-JukMgiCL6y4s-LI-h3Ry00mZScYk07VP_nVTW-v64FMI5-Oeew9CbylZUirYld5OPeiYl4Syhi4ZIatnaFEQVlHB2-doQbjklaRcXKBXKW0JIWIl-Ut0QZui4Kt2gX7ejZN2EQwGb0LuYXDzWBmYyhd8xjudgnGDzi547DwOO4iP4DZ9xtobHNaQAGszDxn386h9wi5hHzIe3Ohysc0Bj3PqdHTedThCB1MOEetN8C7l9Bq9sHpI8Ob0XqJvN58frm-r-69f7q4_3Vdd2SdXYCwzFARIsK22TddoyVZMMGE7a0hTkHotCLcW6q5uNDGSWIBG0rWw0lB-iT4efad5PYLpym5RD2qKbtRxr4J26l_Eu15twk5xWUxoXQzenwxi-D5Dymob5uhLZsVYK0UryGEKP5K6GFKKYM8DKFGH0tSf0tTv0tShtKJ69zTbX82ppUL4cCT05fCPpS019fvkwhA2e3UzD8MD_Mhna9bWqla3VDZCTcYW9dX_1ec8T1T8F4n6wV4</recordid><startdate>20080401</startdate><enddate>20080401</enddate><creator>Van Guilder, Gary P</creator><creator>Stauffer, Brian L</creator><creator>Greiner, Jared J</creator><creator>DeSouza, Christopher A</creator><general>American Physiological Society</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7QR</scope><scope>7TS</scope><scope>7U7</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>P64</scope><scope>5PM</scope></search><sort><creationdate>20080401</creationdate><title>Impaired endothelium-dependent vasodilation in overweight and obese adult humans is not limited to muscarinic receptor agonists</title><author>Van Guilder, Gary P ; Stauffer, Brian L ; Greiner, Jared J ; DeSouza, Christopher A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c522t-edf2d1e5e6ef9af8c8a6272525fcfd08e5e4b503ffe4c48a0d60fee861b5f6d13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Acetylcholine - administration &amp; dosage</topic><topic>Adult</topic><topic>Aged</topic><topic>Blood vessels</topic><topic>Body Mass Index</topic><topic>Bradykinin - administration &amp; dosage</topic><topic>Cells</topic><topic>Dose-Response Relationship, Drug</topic><topic>Endothelium, Vascular - drug effects</topic><topic>Endothelium, Vascular - enzymology</topic><topic>Endothelium, Vascular - metabolism</topic><topic>Endothelium, Vascular - physiopathology</topic><topic>Enzyme Inhibitors - administration &amp; dosage</topic><topic>Female</topic><topic>Forearm - blood supply</topic><topic>Humans</topic><topic>Infusions, Intravenous</topic><topic>Isoproterenol - administration &amp; dosage</topic><topic>Male</topic><topic>Methacholine Chloride - administration &amp; dosage</topic><topic>Middle Aged</topic><topic>Muscarinic Agonists - administration &amp; dosage</topic><topic>NG-Nitroarginine Methyl Ester - administration &amp; dosage</topic><topic>Nitric oxide</topic><topic>Nitric Oxide - metabolism</topic><topic>Nitric Oxide Synthase - antagonists &amp; inhibitors</topic><topic>Nitric Oxide Synthase - metabolism</topic><topic>Nitroprusside - administration &amp; dosage</topic><topic>Obesity</topic><topic>Obesity - metabolism</topic><topic>Obesity - physiopathology</topic><topic>Regional Blood Flow - drug effects</topic><topic>Signal Transduction - drug effects</topic><topic>Studies</topic><topic>Substance P - administration &amp; dosage</topic><topic>Vasodilation - drug effects</topic><topic>Vasodilator Agents - administration &amp; dosage</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Van Guilder, Gary P</creatorcontrib><creatorcontrib>Stauffer, Brian L</creatorcontrib><creatorcontrib>Greiner, Jared J</creatorcontrib><creatorcontrib>DeSouza, Christopher A</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Physical Education Index</collection><collection>Toxicology Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>American journal of physiology. Heart and circulatory physiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Van Guilder, Gary P</au><au>Stauffer, Brian L</au><au>Greiner, Jared J</au><au>DeSouza, Christopher A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Impaired endothelium-dependent vasodilation in overweight and obese adult humans is not limited to muscarinic receptor agonists</atitle><jtitle>American journal of physiology. Heart and circulatory physiology</jtitle><addtitle>Am J Physiol Heart Circ Physiol</addtitle><date>2008-04-01</date><risdate>2008</risdate><volume>294</volume><issue>4</issue><spage>H1685</spage><epage>H1692</epage><pages>H1685-H1692</pages><issn>0363-6135</issn><eissn>1522-1539</eissn><coden>AJPPDI</coden><abstract>1 Integrative Vascular Biology Laboratory, Department of Integrative Physiology, University of Colorado, Boulder; 2 Department of Medicine, University of Colorado Health Sciences Center, and 3 Division of Cardiology, Department of Medicine, Denver Health and Hospital Authority, Denver, Colorado Submitted 1 November 2007 ; accepted in final form 13 February 2008 Muscarinic receptor agonists have primarily been used to characterize endothelium-dependent vasodilator dysfunction with overweight/obesity. Reliance on a single class of agonist, however, yields limited, and potentially misleading, information regarding endothelial vasodilator capacity. The aims of this study were to determine 1 ) whether the overweight/obesity-related reduction in endothelium-dependent vasodilation extends beyond muscarinic receptor agonists and 2 ) whether the contribution of nitric oxide (NO) to endothelium-dependent vasodilation is reduced in overweight/obese adults. Eighty-six middle-aged and older adults were studied: 42 normal-weight (54 ± 1 yr, 21 men and 21 women, body mass index = 23.4 ± 0.3 kg/m 2 ) and 44 overweight/obese (54 ± 1 yr, 28 men and 16 women, body mass index = 30.3 ± 0.6 kg/m 2 ) subjects. Forearm blood flow (FBF) responses to intra-arterial infusions of acetylcholine in the absence and presence of the endothelial NO synthase inhibitor N G -monomethyl- L -arginine, methacholine, bradykinin, substance P, isoproterenol, and sodium nitroprusside were measured by strain-gauge plethysmography. FBF responses to each endothelial agonist were significantly blunted in the overweight/obese adults. Total FBF (area under the curve) to acetylcholine (50 ± 5 vs. 79 ± 4 ml/100 ml tissue), methacholine (55 ± 4 vs. 86 ± 5 ml/100 ml tissue), bradykinin (62 ± 5 vs. 85 ± 4 ml/100 ml tissue), substance P (37 ± 4 vs. 57 ± 5 ml/100 ml tissue), and isoproterenol (62 ± 4 vs. 82 ± 6 ml/100 ml tissue) were 30%-40% lower in the overweight/obese than normal-weight adults. N G -monomethyl- L -arginine significantly reduced the FBF response to acetylcholine to the same extent in both groups. There were no differences between the groups in the FBF responses to sodium nitroprusside. These results indicate that agonist-stimulated endothelium-dependent vasodilation is universally impaired with overweight/obesity. Moreover, this impairment appears to be independent of NO. cell surface receptors; intracellular signaling pathways; nitric oxide Address for reprint requests and other correspondence: C. A. DeSouza, Dept. of Integrative Physiology, Univ. of Colorado, 354 UCB, Boulder, CO 80309 (e-mail: desouzac{at}colorado.edu )</abstract><cop>United States</cop><pub>American Physiological Society</pub><pmid>18281379</pmid><doi>10.1152/ajpheart.01281.2007</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0363-6135
ispartof American journal of physiology. Heart and circulatory physiology, 2008-04, Vol.294 (4), p.H1685-H1692
issn 0363-6135
1522-1539
language eng
recordid cdi_highwire_physiology_ajpheart_294_4_H1685
source MEDLINE; American Physiological Society; Alma/SFX Local Collection; EZB Electronic Journals Library
subjects Acetylcholine - administration & dosage
Adult
Aged
Blood vessels
Body Mass Index
Bradykinin - administration & dosage
Cells
Dose-Response Relationship, Drug
Endothelium, Vascular - drug effects
Endothelium, Vascular - enzymology
Endothelium, Vascular - metabolism
Endothelium, Vascular - physiopathology
Enzyme Inhibitors - administration & dosage
Female
Forearm - blood supply
Humans
Infusions, Intravenous
Isoproterenol - administration & dosage
Male
Methacholine Chloride - administration & dosage
Middle Aged
Muscarinic Agonists - administration & dosage
NG-Nitroarginine Methyl Ester - administration & dosage
Nitric oxide
Nitric Oxide - metabolism
Nitric Oxide Synthase - antagonists & inhibitors
Nitric Oxide Synthase - metabolism
Nitroprusside - administration & dosage
Obesity
Obesity - metabolism
Obesity - physiopathology
Regional Blood Flow - drug effects
Signal Transduction - drug effects
Studies
Substance P - administration & dosage
Vasodilation - drug effects
Vasodilator Agents - administration & dosage
title Impaired endothelium-dependent vasodilation in overweight and obese adult humans is not limited to muscarinic receptor agonists
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-17T20%3A43%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_highw&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Impaired%20endothelium-dependent%20vasodilation%20in%20overweight%20and%20obese%20adult%20humans%20is%20not%20limited%20to%20muscarinic%20receptor%20agonists&rft.jtitle=American%20journal%20of%20physiology.%20Heart%20and%20circulatory%20physiology&rft.au=Van%20Guilder,%20Gary%20P&rft.date=2008-04-01&rft.volume=294&rft.issue=4&rft.spage=H1685&rft.epage=H1692&rft.pages=H1685-H1692&rft.issn=0363-6135&rft.eissn=1522-1539&rft.coden=AJPPDI&rft_id=info:doi/10.1152/ajpheart.01281.2007&rft_dat=%3Cproquest_highw%3E1460409201%3C/proquest_highw%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=229659501&rft_id=info:pmid/18281379&rfr_iscdi=true